


## AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I:




wherein

R<sub>a</sub> is H; C<sub>1-4</sub>-alkyl; or C<sub>1-4</sub>-alkyl substituted by OH, NH<sub>2</sub>, NHC<sub>1-4</sub>-alkyl or N(C<sub>1-4</sub>-alkyl)<sub>2</sub> methyl, ethyl or isopropyl;

R<sub>b</sub> is H; halogen; C<sub>1-6</sub>-alkyl; or C<sub>1-6</sub>-alkoxy, Cl, methyl or ethyl; and

R is a radical of formula (a):



wherein

R<sub>1</sub> is ~~piperazine~~ or 4-methyl-piperazin-1-yl; and


R<sub>2</sub> is halogen; C<sub>1-4</sub>-alkyl; C<sub>1-4</sub>-alkoxy; CF<sub>3</sub>; nitrile; nitro; or amino;  
or a salt thereof.

2-4. (Canceled)

5. (Previously presented) A compound according Claim 1, wherein R<sub>2</sub> is Cl; F; CF<sub>3</sub>; nitrile; nitro; or amino; or a salt thereof.

6. (Previously presented) A process for the preparation of a compound of

formula I according to claim 1, which process comprises reacting a compound of formula II



wherein  $R_a$  and  $R_b$  are as defined in claim 1,  
with a compound of formula III



wherein R is as defined in claim 1,  
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or *vice versa*, as appropriate.


7. (Previously presented) A compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical.
8. (Previously presented) A pharmaceutical composition comprising a compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.
9. (Canceled)
10. (Currently amended) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of

formula I of according to Claims 1 or a pharmaceutically-acceptable salt thereof.

11. (Previously presented) A method for treating acute or chronic transplant rejection, psoriasis, or uveitis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.

12. (Previously presented) A compound according to Claim 1 that is 3-(1H-indol-3-yl)-4-[6-(4-methyl-piperazin-1-yl)-3-trifluoromethyl-pyridin-2-yl]-pyrrole-2,5-dione, or a pharmaceutically-acceptable salt thereof.

13. (New) A compound of formula I according to Claim 1, selected from the compounds of formula A:



wherein the substituents for each compound thereof have the following values:

Compound	R <sub>a</sub>	R <sub>b</sub>	R <sub>2</sub>	R <sub>5</sub>	R <sub>6</sub>	R <sub>7</sub>
1	H	CH <sub>3</sub>	CF <sub>3</sub>	CH <sub>3</sub>	H	H
2	H	Cl	CF <sub>3</sub>	CH <sub>3</sub>	H	H
3	H	H	CF <sub>3</sub>	H	-CH <sub>2</sub> -CH <sub>2</sub> -	
4	H	CH <sub>3</sub>	CF <sub>3</sub>	H	-CH <sub>2</sub> -CH <sub>2</sub> -	
5	H	CH <sub>2</sub> -CH <sub>3</sub>	CF <sub>3</sub>	H	-CH <sub>2</sub> -CH <sub>2</sub> -	
6	H	CH <sub>3</sub>	F	CH <sub>3</sub>	H	H
7	H	H	F	CH <sub>3</sub>	H	H
8	H	CH <sub>2</sub> -CH <sub>3</sub>	F	CH <sub>3</sub>	H	H
9	H	H	Cl	CH <sub>3</sub>	H	H
10	H	CH <sub>2</sub> -	Cl	CH <sub>3</sub>	H	H

		CH <sub>3</sub>				
11	H	CH <sub>3</sub>	Cl	CH <sub>3</sub>	H	H
12	CH <sub>3</sub>	H	F	CH <sub>3</sub>	H	H
13	H	Cl	F	CH <sub>3</sub>	H	H
14	H	CH <sub>3</sub>	H	CH <sub>3</sub>	H	H
15	H	H	H	CH <sub>3</sub>	H	H
16	H	CH <sub>3</sub>	CH <sub>3</sub>	CH <sub>3</sub>	H	H
17	H	H	CH <sub>3</sub>	CH <sub>3</sub>	H	H
18	CH <sub>3</sub>	H	CH <sub>3</sub>	CH <sub>3</sub>	H	H
19	H	CH <sub>3</sub>	NO <sub>2</sub>	CH <sub>3</sub>	H	H
20	CH <sub>3</sub>	H	NO <sub>2</sub>	CH <sub>3</sub>	H	H
21	H	H	NO <sub>2</sub>	CH <sub>3</sub>	H	H
22	CH <sub>3</sub>	H	NH <sub>2</sub>	CH <sub>3</sub>	H	H
23	H	CH <sub>3</sub>	NH <sub>2</sub>	CH <sub>3</sub>	H	H
24	H	H	NH <sub>2</sub>	CH <sub>3</sub>	H	H
25	H	H	CN	CH <sub>3</sub>	H	H
26	H	CH <sub>3</sub>	CN	CH <sub>3</sub>	H	H
27	CH <sub>3</sub>	H	CN	CH <sub>3</sub>	H	H

or a salt thereof.

14. (New) A compound according to Claim 13, wherein R<sub>a</sub> is H, R<sub>b</sub> is H, R<sub>2</sub> is F, R<sub>5</sub> is CH<sub>3</sub>, R<sub>6</sub> is H and R<sub>7</sub> is H; or R<sub>a</sub> is H, R<sub>b</sub> is H, R<sub>2</sub> is Cl, R<sub>5</sub> is CH<sub>3</sub>, R<sub>6</sub> is H and R<sub>7</sub> is H.